K. Kalinsky

Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer

Jessica Armand, Sungsoo Kim, Kibum Kim, Eugene Son et autres

CDK4/6 inhibitors (CDK4/6i) with endocrine therapy are standard for hormone receptor-positive (HR + ) metastatic breast cancer. However, most patients eventually develop resistance and discontinue treatment, and there is currently no consensus on effective second-line strategies. Using preclinical HR + human breast …

us (code pays fourni par la source)

Understanding first-line treatment patterns and survival outcomes across sociodemographic groups of women with metastatic triple-negative breast cancer in the United States: a real-world study

Sara M. Tolaney, Laura M. Spring, Yara George Abdou, M K Rehnquist et autres

BACKGROUND: Triple-negative breast cancer (TNBC) has poor prognosis, and disproportionately affects young black women and BRCA1/2 mutation carriers. We describe sociodemographic differences in real-world treatment patterns and survival outcomes in women with metastatic TNBC (mTNBC) in the United States. PATIENTS AND METHODS: …

us, gb (code pays fourni par la source)

6MO Baseline ctDNA and methylation status as predictors of treatment benefit in the phase III post MONARCH trial of abemaciclib + fulvestrant in advanced breast cancer patients

Seth Andrew Wander, E.P. Hamilton, Giampaolo Bianchini, K. Kalinsky et autres

ctDNA Predicts Pain Response in a Multi-Institutional Phase II Trial of Palliative Radiation, Palbociclib and Hormone Therapy in Metastatic Breast Cancer

M. Torres, Sarah E. Friend, Andrezj Niemierko, J.Y. Lin et autres

351P Abemaciclib plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Subgroup analyses from the phase III postMONARCH trial

Giampaolo Bianchini, M. Martín Jiménez, Stephanie L. Graff, R. Jeselsohn et autres

it, es, us, Afrique du Sud (code pays fourni par la source)

LBA2 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in pretreated, inoperable/metastatic HR+/HER2– breast cancer (BC): Additional safety analysis from TROPION-Breast01

Komal L. Jhaveri, A. Bardia, S-A. Im, Michelino De Laurentiis et autres

In TROPION-Breast01 (NCT05104866), the antibody-drug conjugate Dato-DXd showed improved efficacy and was well tolerated compared with investigator’s choice of CT (ICC) in patients (pts) with HR+/HER2– BC. Here we report additional safety analyses.

us, kr, es, it, cn, ca, jp, tw, gb, fr (code pays fourni par la source)

Sacituzumab govitecan in metastatic triple-negative breast cancer

F. Dalenc, LA Carey, J. O apos Shaughnessy, L.M. Itri et autres

BACKGROUND: Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab govitecan is an antibody-drug conjugate composed of an antibody targeting the human trophoblast cell-surface antigen 2 (Trop-2), which is expressed in the majority of breast cancers, coupled to SN-38 (topoisomerase …

us (code pays fourni par la source)

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

P. Aftimos, L. Vahdat, V. Diéras, J. O apos Shaughnessy et autres

us (code pays fourni par la source)